

Current report

according to ASF Regulation no. 5/2018

Report date:	12.08.2021
Name of issuer:	Farmaceutica REMEDIA S.A.
Registered office:	Deva, no. 2, Nicolae Bălcescu Blvd
Tel/ fax no:	+40 254 22 32 60 / +40 254 22 61 97
ORC no:	2115198
Trade Registry no:	J20 / 700 / 1991
Subscribed and paid-in capital:	LEI 9.548.082
Regulated market:	Bucharest Stock Exchange, Standard Category

Important events to report:

RELEASE

The Board of Directors of Farmaceutica REMEDIA S.A. informs that the Report for the 1st Semester of 2021 - the full version - is available on its own website <http://www.remEDIA.ro/en/investors-2-2/company-financials/> and in the link from the IRIS platform, below.

During 01.01.2021 – 30.06.2021, the commercial company Farmaceutica REMEDIA S.A. recorded the following consolidated financial results:

Crt. No.	Indicator	Realisations Jan-June 2021 (Lei)	Realisations Jan-June 2020 (Lei)**	Evolution 2021/2020 (%)
1.	Net sales of goods *	217.017.742	219.985.237	- 7,06
2.	Other operating revenues	2.617.812	1.414.745	46,0%
3.	Total operating income	219.635.554	221.399.983	-0,8%
4.	Total operational costs *	214.558.867	222.345.978	-3,6%
5.	Operating result	5.076.687	-945.995	118,6%
6.	Financial result	-1.554	-113.631	371,9%
7.	Gross result	5.018.886	-1.103.137	122,0%

* Including trade discounts granted/received

The economic - financial indicators on 30.06.2021 are presented in the following table:

LIQUIDITY AND WORKING CAPITAL	Farmaceutica REMEDIA SA	Farmaceutica REMEDIA Distribution & Logistics SRL
Current liquidity (Current assets / Current debts)	1,75	1,05
Current assets	12.955.158	180.770.605
Current debts	7.414.931	172.768.690

Degree of indebtedness (Borrowed capital / Equity x 100)	0,00%	0,00%
Borrowed capital	0	0
Equity	53.299.019	8.564.131
Turnover speed for client debit items (Average customer balance /turnover *180)	74 days	104 days
Average customer balance	1.943.715	125.246.511
Net turnover	4.711.461	217.100.348
Turnover speed of stocks (average stock/ net COGS)*180	124 days	33 days
Average stock	1.775.484	36.761.633
COGS net	2.568.092	198.945.37

*including financial leasing

Notes:

1) **Current liquidity** – the indicator level reflects a good payment capacity, therefore a reduced risk for creditors in case of FR, certifying that the company is able to cover their short-term debts based on receivables and cash availabilities. The indicator evolved positively compared to the same period of last year (1,25). In the case of FRDL the indicator presents a medium risk, remaining at the same level compared to the same period of the previous financial year.

2) **Degree of indebtedness** expresses the effectiveness of credit risk management, indicating potential financing, liquidity problems, with influences in honouring the assumed commitments. In the case of both companies there is no risk. In the calculation of this indicator, the borrowed capital includes both bank loans and debts from financial leasing.

3) **Turnover speed for client debit items** expresses company effectiveness in collecting its receivables, respectively the number of days until the date on which debtors pay their debts to the company. Considering the dynamics of sales and the specifics of receivables in the distribution of medicines, we consider that the value of the indicator is normal for both companies, under the given conditions. Compared to the same period last year, the indicator deteriorated in the case of FR (from 47 days) and improved in the case of FRDL (from 116 days).

4) The value of the indicator **No. of days of storage** can be considered to be in line with the specific activity. Compared to June 2020, the indicator has deteriorated in the case of FR, the increase in the indicator is caused by the decrease in the number of pharmaceutical units, but has improved in the case of FRDL (from 47 days).

Chairman of the Board of Administrators,

„TARUS” – Valentin Norbert TARUS e.U.